Topotecan Gets Expanded Indication for Combined Therapy of Cervical Cancer

Publication
Article
OncologyONCOLOGY Vol 20 No 8
Volume 20
Issue 8

The US Food and Drug Administration (FDA) has approved topotecan HCl (Hycamtin) in combination with cisplatin, for the treatment of stage IVB, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Following a 6-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using topotecan in combination with cisplatin compared to cisplatin alone.

The US Food and Drug Administration (FDA) has approved topotecan HCl (Hycamtin) in combination with cisplatin, for the treatment of stage IVB, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy. Following a 6-month priority review by the FDA, the expanded indication is based on phase III results that demonstrated a survival advantage by using topotecan in combination with cisplatin compared to cisplatin alone.

Articles in this issue
Erythropoiesis-Stimulating Protein Support and Survival
Advances in the Management of Chemotherapy-Induced Anemia and Its Treatment
Sunitinib Proves Beneficial in Advanced Kidney Cancer, Promising in Lung Cancer
Anastrozole Does Not Cause Osteoporosis in Breast Cancer Patients With Normal Bone Mineral Density at Outset
Capecitabine/Cisplatin Effective in Advanced Gastric Cancer Patients
Bevacizumab/Chemo Combination Approved for Treating Metastatic Colorectal Cancer
The HPV Vaccine: A Model of Research and Prevention
Topotecan Gets Expanded Indication for Combined Therapy of Cervical Cancer
Protein-Bound Paclitaxel Promising as First-Line Treatment in Non-Small-Cell Lung Cancer
Temsirolimus Prolongs Survival of Patients With Advanced Renal Cell Carcinoma
Imatinib Sets New Treatment Standard in Patients With Chronic Myeloid Leukemia
Lapatinib Nearly Doubles Time to Progression for Patients With HER2-Positive Advanced Breast Cancer
Updated Overall Survival Analysis Presented on Sorafenib Trial
Interim Data Suggest Potential Benefits of Darbepoetin Dosed Every 3 Weeks With Intravenous Iron
Integrative Oncology: Principles and Practice
Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content
Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

Clinicians Consider Identification, Management of RCC Through the Patient’s Eyes

ONCOLOGY Staff
March 8th 2025
Article

James Zoeller discussed various aspects of his cancer care after a RCC diagnosis with Hannah D. McManus, MD, and Allison Brown, BSN, RN, RN-BC.

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Updates in Surgical Management of the Axilla

Updates in Surgical Management of the Axilla

Anita Mamtani, MD;Andrea V. Barrio, MD
March 6th 2025
Article

Axillary management of patients with breast cancer such as sentinel lymph node biopsy have evolved substantially over the past 30 years.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Empowering Awareness to Address Rising Gynecological Cancer Incidence

Ginger J. Gardner, MD, FACOG
October 28th 2024
Podcast

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Ariana Pelosci
February 24th 2025
Article

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.